Abstract
Arsenic has recently been identified as an effective drug in the treatment of newly diagnosed and relapsed acute promyelocytic leukemia. Indeed, arsenic trioxide combined with all-trans retinoic acid shows a synergistic effect. Mechanistically, arsenic targets the key leukemogenic protein PML-RARalpha, setting up a new example of molecular target-based cancer therapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / therapeutic use*
-
Arsenic Trioxide
-
Arsenicals / administration & dosage
-
Arsenicals / adverse effects
-
Arsenicals / pharmacokinetics
-
Arsenicals / therapeutic use*
-
Clinical Trials as Topic
-
Humans
-
Leukemia, Promyelocytic, Acute / drug therapy*
-
Oxides / administration & dosage
-
Oxides / adverse effects
-
Oxides / pharmacokinetics
-
Oxides / therapeutic use*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Arsenicals
-
Oxides
-
Arsenic Trioxide